Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX and SBRT for Pancreatic Cancer
NCT04130399Phase 2Withdrawn
- Sponsor
- Indiana University
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pancreatic ductal adenocarcinoma (PDAC), sponsored by Indiana University. Primary endpoint: Local control rate. Planned start Jul 2019; status: withdrawn.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04130399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130399.